Sinovac biotech ltd (SVA)
Balance Sheet / Quarterly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
ASSETS
Current assets
Cash and cash equivalents

114,415

62,434

63,834

91,293

107,242

91,241

104,286

101,585

Restricted cash (note 4)

1,549

3,007

1,626

0

-

-

-

-

Short-term investments (note 3)

-

-

-

-

-

-

-

1,512

Accounts receivable - net (notes 5)

66,205

49,832

39,021

40,719

31,927

23,440

17,834

22,370

Inventories (note 6)

19,618

14,102

18,655

18,712

14,329

10,530

8,113

14,541

Due from related party (note 12(a))

-

-

-

-

-

-

-

3,397

Prepaid expenses and deposits (including prepaid expenses to related party of 2017 - $366, 2016 - $343) (note 11 (b))

2,101

1,372

958

1,426

1,150

1,072

1,804

887

Deferred tax assets (note 14)

-

-

2,603

2,266

2,602

-

-

-

Current assets held for sale (note 4)

-

-

1,797

387

-

-

-

-

Deferred tax assets (note 10)

-

-

-

-

-

-

-

2,682

Total current assets

203,888

130,747

128,494

154,803

157,250

126,283

132,039

146,976

Property, plant and equipment (notes 8)

76,430

66,882

63,913

66,233

67,963

69,171

75,627

64,036

Prepaid land lease payments (notes 9)

9,028

8,697

9,574

10,261

10,948

10,912

-

-

Long-term inventories (note 7)

0

98

0

2,648

2,781

28

5,248

395

Long-term prepaid expenses (including prepaid expenses to related party of 2017 - $25, 2016 - $23) (note 11(b))

25

23

25

3

154

290

408

517

Prepayments for acquisition of equipment

528

964

328

1,387

708

483

828

576

Deferred tax assets (note 13)

9,320

3,944

593

515

117

446

419

-

Licenses (note 10)

-

-

-

352

772

1,150

-

-

Long-term assets held for sale (note 3)

-

-

-

2,328

-

-

-

-

Licenses (note 7)

-

-

-

-

-

-

1,336

-

Deferred tax assets (note 10)

-

-

-

-

-

-

-

507

Licenses and permits (note 8)

-

-

-

-

-

-

-

1,348

Total assets

299,219

211,355

202,927

238,530

240,693

208,763

215,908

214,357

LIABILITIES AND EQUITY
Current liabilities
Short-term bank loans (note 10)

18,152

31,279

21,775

47,375

16,217

3,329

-

-

Loan from a non-controlling shareholder (note 11 (a))

0

2,304

2,470

2,595

3,324

-

-

-

Loans payable (note 8)

-

-

-

-

-

-

4,713

10,435

Accounts payable and accrued liabilities (note 12)

59,418

24,960

22,661

22,538

28,037

24,778

29,522

22,091

Income tax payable

8,862

3,178

1,643

1,101

246

239

3,351

958

Deferred revenue (note 14)

4,073

2,766

8,144

4,996

875

1,378

429

-

Deferred revenue (note 20)

-

-

-

-

-

-

-

9,707

Deferred tax liability (note 10)

-

-

-

-

-

-

-

1,005

Dividends payable

-

-

-

-

-

-

795

-

Deferred government grants (note 15)

2,038

1,777

1,202

530

458

431

719

-

Current liabilities held for sale (note 4)

-

-

243

699

-

-

-

-

Deferred government grants (note 19)

-

-

-

-

-

-

-

1,559

Total current liabilities

92,543

66,264

58,138

79,834

49,157

30,155

39,530

45,757

Deferred government grants (note 15)

4,474

2,953

4,730

7,494

4,746

4,069

3,388

2,464

Long-term bank loans (note 10)

14,849

9,448

756

1,803

32,146

31,181

17,321

10,057

Long term payable for acquisition of assets

-

-

-

-

-

-

-

4,842

Deferred revenue (note 14)

0

89

0

7,191

11,005

10,693

10,369

3,478

Loan from a non-controlling shareholder (note 11 (a))

7,070

0

-

-

-

3,230

-

-

Other non-current liabilities (note 13)

3,143

2,935

2,798

454

-

-

-

-

Long-term liabilities held for sale (note 3)

-

-

-

28

-

-

-

-

Total long-term liabilities

29,536

15,425

8,284

16,970

47,897

49,173

31,079

20,843

Total liabilities

122,079

81,689

66,422

96,804

97,054

79,328

70,610

66,601

Commitments and contingencies (notes 16 and 23)

0

0

0

0

0

0

0

0

EQUITY
Preferred stock Authorized 50,000,000 shares at par value of $0.001 each Issued and outstanding: nil

0

0

0

0

0

0

0

0

Common stock (note 17) Authorized: 100,000,000 shares at par value of $0.001 each Issued and outstanding: 57,281,861 (2016 -57,011,761)

57

57

57

56

56

55

54

54

Additional paid-in capital

115,339

112,668

109,944

108,243

107,393

106,246

105,383

104,152

Accumulated other comprehensive income

7,075

168

8,182

12,022

14,141

11,771

9,978

6,883

Statutory surplus reserves (note 19)

19,549

14,788

13,450

12,627

11,808

11,808

11,808

-

Statutory surplus reserves (note 18)

-

-

-

-

-

-

-

11,473

Accumulated earnings (deficit)

9,132

-11,914

-9,980

-6,384

-

-

-

3,876

Accumulated deficit

-

-

-

-

-4,714

-12,156

2,696

-

Total shareholders' equity

151,152

115,767

121,653

126,564

128,684

117,724

129,920

126,439

Non-controlling interests (note 20)

25,988

13,899

14,852

15,162

14,955

11,711

15,376

21,316

Total equity

177,140

129,666

136,505

141,726

143,639

129,435

145,297

147,756

Total liabilities and equity

299,219

211,355

202,927

238,530

240,693

208,763

215,908

214,357